Vitalize Raises $31 Million Series A Led by Oak HC/FT to Automate Hospital Staffing and Scheduling

Hospitals spend more on labor than on anything else, and much of that work is still planned by hand. Vitalize, a San Francisco healthtech company, raised a $31 million Series A to automate staffing, scheduling and capacity planning, with coverage appearing in early October 2026.

Oak HC/FT led the round, and Norwest, .406 Ventures, Constellation Ventures, Y Combinator, Rock Health Capital and the MemorialCare Innovation Fund also took part.

What the Product Does

Vitalize's platform handles staffing, scheduling and hospital capacity planning. Its software forecasts patient demand and automates scheduling, and it connects to electronic medical record systems and time and payroll platforms. The company says it is meant to replace more than ten separate tools that clinical teams might otherwise use, and that it manages millions of shifts a week across dozens of large health systems.

The Market Argument

Vitalize estimates that labor makes up 50% to 60% of U.S. hospital operating expenses, close to $1 trillion of annual spending. That is the company's estimate, and the size of the opportunity depends on how much of that spending software can actually reduce.

Customer Results to Treat With Caution

According to the company, Rochester Regional Health cut manual staffing time by 50%, and St. Luke's Health cut premium labor costs by 54%. These results come from Vitalize and have not been independently verified. Founders should read results like these as a sales claim until a hospital or third party confirms how they were measured.

Where the Money Goes

The company plans to grow its growth and deployment teams and keep building models for patient throughput. Deployment staff matter in this market because a hospital usually has to connect several systems before software works, which makes onboarding a real cost.

Why Investors Back This Category

Hospital labor is a large, measurable cost, and many health systems have tightened budgets while demand for care keeps rising. A product that helps a hospital use staff and beds more efficiently speaks to a problem its finance team already tracks, and that makes the first sale easier to defend internally. The challenge is the work after the sale: each new hospital brings its own systems and rules, so the company's growth will depend on how repeatable its deployments become.

What This Means for Founders

For health technology founders, the lesson is that large institutions buy software that removes spending they already track. A product tied to labor cost is easier to justify than one that promises better outcomes without a clear price. If you are raising a Series A, show a customer's before-and-after numbers, how long deployment took and how much recurring revenue came after the first contract. Ask each lead investor how it judges long sales cycles, and consider the dilution of a round sized to cover deployment costs.

Read the baseline mechanics of a limited partner if the term is new, or explore active capital on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai